Company profile

Essen Biotech

Privately held: no public share price (AML registry sponsor; ownership/ticker not yet curated.)

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
CD123/CD33 CART
Phase 2
CD123 / CD33
Acute Myeloid Leukemia
EB-SELECT Dual-Target CAR-NK Cells
Phase 2
Undisclosed / early pipelineCell therapy
Multiple Myeloma
EB-SELECT Single-Target CAR-NK Cells
Phase 2
Personalized, biomarker-guided allogeneic chimeric antigen receptorCell therapy
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.